News
Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™
26-02-2013
Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Health Canada for its new clinical study with ATIR™. This study will be a Phase II...
read more 
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
21-01-2013
Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regarding the Company’s lead product...
read more
- Kiadis Pharma Raises EUR 10 Million in Financing Round
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium
- Kiadis Pharma presents at the EBMT in Göteborg
Kiadis Pharma
Entrada 231-234
1096 EG Amsterdam
The Netherlands
T +31 (0)20 314 02 50
F +31 (0)20 314 02 51
